12.4 Nonprescription, Behind-the-Counter & Restricted OTC Dispensing
Key Takeaways
- Rule 1140-03-.12(2) lets a pharmacist dispense a controlled substance that is not a prescription drug under the FDCA without a prescription, provided the pharmacist complies with 21 CFR § 1306.32 and other applicable law.
- Under 21 CFR § 1306.32 the purchaser must be at least 18, the sale must be made by the pharmacist personally, quantities are capped at 240 mL or 48 dosage units of an opium-containing preparation (or 120 mL or 24 dosage units of any other controlled substance) in a 48-hour period, and a bound record book is required.
- Rule 1140-03-.08 requires all repackaging to be supervised and controlled by a pharmacist with in-process and end-process verification and documentation, and permits a pharmacy batch number in lieu of the manufacturer name and lot number if a readily retrievable cross-reference exists.
- Gabapentin is a Schedule V controlled substance in Tennessee under T.C.A. § 39-17-414, so it is dispensed on a prescription and reported to the CSMD like any other Schedule V drug.
- Federal OTC labeling is governed by the standardized Drug Facts panel at 21 CFR § 201.66, and OTC products remain subject to the misbranding provisions of 21 U.S.C. § 352.
12.4 Nonprescription, Behind-the-Counter & Restricted OTC Dispensing
Quick Answer: Tennessee does not maintain a general "behind-the-counter" drug class. What it has instead are three specific restricted-sale regimes, each with its own authority. Rule 1140-03-.12(2) allows a pharmacist to dispense a controlled substance that is not a prescription drug under the FDCA without a prescription, provided the pharmacist complies with 21 CFR § 1306.32. Rule 1140-03-.12(3) and (4) put injection devices and all insulin preparations behind the public-access line. And T.C.A. § 39-17-431 puts pseudoephedrine and ephedrine products behind the counter with NPLEx stop-sale controls. Everything else marketed over the counter is governed federally by the Drug Facts labeling requirements of 21 CFR § 201.66 and the misbranding provisions of the FDCA.
1. The Exempt Narcotic Sale — Rule 1140-03-.12(2) and 21 CFR § 1306.32
Certain Schedule V preparations — classically antidiarrheals and antitussives containing limited quantities of opium or codeine — are not "prescription drugs" under the Federal Food, Drug, and Cosmetic Act. Federal law permits a pharmacist to dispense them without a prescription, and Tennessee adopts that authority by reference:
Rule 1140-03-.12(2): "A controlled substance which is not a prescription drug under the Federal Food, Drug, and Cosmetic Act may be dispensed by a pharmacist without a prescription to a patient provided the pharmacist complies with the provisions of 21 CFR § 1306.32 and any other applicable law."
The federal conditions in § 1306.32 are the substance of the answer to any exam item on this topic:
| Condition | Requirement |
|---|---|
| Who dispenses | The dispensing must be made by a pharmacist; after the pharmacist fulfills the professional and technical responsibilities, the actual cash or credit transaction and delivery may be completed by a non-pharmacist |
| Purchaser age | Not less than 18 years old |
| Identification | The pharmacist must require suitable identification from any purchaser not known to the pharmacist |
| Quantity — opium preparations | Not more than 240 mL (8 fl oz) or 48 dosage units to the same purchaser in any 48-hour period |
| Quantity — other controlled substances | Not more than 120 mL (4 fl oz) or 24 dosage units to the same purchaser in any 48-hour period |
| Purpose | Dispensed only for a medical purpose |
| Record | A bound record book for these dispensings, kept separate from other records, containing the purchaser's name and address, the name and quantity of the product, the date, and the name or initials of the dispensing pharmacist, retained two years |
Two traps recur. First, the 48-hour window is not a calendar day and not a 30-day window — the shorter opium/non-opium quantity distinction is the point of the rule. Second, the transaction may be completed by a clerk, but the professional judgment and the decision to dispense belong to the pharmacist personally, which parallels Rule 1140-02-.01(13).
Tennessee wrinkle — gabapentin. Tennessee scheduled gabapentin as a Schedule V controlled substance under T.C.A. § 39-17-414 (2018). It is not an exempt narcotic and is not dispensable without a prescription; it is a Schedule V prescription drug that must be dispensed on a valid order and reported to the CSMD like any other Schedule V. Candidates who reason "Schedule V, therefore over the counter" will answer incorrectly.
2. What "Behind-the-Counter" Means in Tennessee
The phrase has no single statutory definition in Tennessee. It is a practical description of four distinct legal regimes:
┌─────────────────────────────────────────────────────────────────────────────┐
│ WHY A PRODUCT SITS BEHIND THE COUNTER IN TENNESSEE │
├──────────────────────────────┬──────────────────────────────────────────────┤
│ Pseudoephedrine / ephedrine │ T.C.A. § 39-17-431: sale limited to a │
│ (Scheduled Listed Chemical │ pharmacy or NPLEx retailer; 3.6 g/day, │
│ Products) │ 7.2 g/30 days, 43.2 g/year; NPLEx entry and │
│ │ binding electronic stop-sale. See § 12.2. │
├──────────────────────────────┼──────────────────────────────────────────────┤
│ Exempt Schedule V narcotic │ Rule 1140-03-.12(2) + 21 CFR 1306.32: │
│ preparations │ pharmacist sale, 18+, ID, 48-hour quantity │
│ │ caps, bound record book. │
├──────────────────────────────┼──────────────────────────────────────────────┤
│ Injection devices │ Rule 1140-03-.12(3): not accessible to the │
│ (needles and syringes) │ public; sold only on PROOF OF MEDICAL NEED. │
├──────────────────────────────┼──────────────────────────────────────────────┤
│ All insulin preparations │ Rule 1140-03-.12(4): not accessible to the │
│ │ public; sold only by a pharmacist, intern, │
│ │ or technician under direct supervision. │
└──────────────────────────────┴──────────────────────────────────────────────┘
Naloxone sits in a fifth category and should not be confused with these. It is dispensed under the statewide standing order issued by the Chief Medical Officer of the Tennessee Department of Health pursuant to T.C.A. § 63-1-152, discussed in section 6.3 — a prescription product dispensed without a patient-specific prescription, not a nonprescription product.
3. Labeling and Packaging of Nonprescription Products
Competency 3.8 reaches the labeling and the packaging and repackaging of nonprescription products, not merely their sale.
Federal OTC Labeling — the Drug Facts Panel
21 CFR § 201.66 prescribes a standardized Drug Facts panel with a fixed heading order: Active ingredient(s) (with purpose), Uses, Warnings, Directions, Other information, Inactive ingredients, and Questions? A product that omits required warnings or bears misleading claims is misbranded under 21 U.S.C. § 352, and a pharmacy that continues to offer it for sale participates in that misbranding.
The Tennessee dispensing-label rule at Rule 1140-03-.06 applies to "the dispensing label for a medical or prescription order." An OTC product sold in the manufacturer's package is not dispensed pursuant to an order and therefore is not relabeled; if a prescriber writes an order for an OTC product and the pharmacy dispenses it as a prescription, the Rule 1140-03-.06 label attaches.
Repackaging — Rule 1140-03-.08
Any repackaging of prescription drugs, devices, and related materials "must be supervised and controlled by a pharmacist with in-process and end-process verification and documentation," and all repackaging must be performed by a pharmacist or by an intern or technician under the supervision of a pharmacist. The pharmacy must have "proper facilities, qualified personnel, effectual operational practices, suitable packaging material, and adequate control procedures" so that purity, integrity, safety, and effectiveness are not affected.
For product repackaged by an institutional pharmacy for subsequent dispensing and use within the institution, the label must include:
| Rule 1140-03-.08(2) | Required label element |
|---|---|
| (a) | Name, strength, and quantity of the drug or device (if larger than one) in the container |
| (b) | The manufacturer's name and lot or control number |
| (c) | The expiration date of the drug or device being repackaged |
| (d) | Cautionary notations (e.g., refrigerate, shake well, not for injection), if applicable |
Rule 1140-03-.08(3) supplies the practical alternative: a batch number assigned by the pharmacy practice site may appear in lieu of the manufacturer's name and lot number, provided the site maintains a readily retrievable record identifying, by batch number, the manufacturer and lot number.
Child-Resistant Packaging Reaches OTC Products Too
The Poison Prevention Packaging Act is not limited to prescription drugs. Household substances and many OTC oral products — including, for example, aspirin and acetaminophen preparations above specified thresholds and iron-containing products — require child-resistant packaging under 16 CFR Part 1700. Manufacturers may market one package size in non-child-resistant packaging if it is conspicuously labeled as intended for households without young children and a child-resistant size is also supplied. Section 8.2 covers the waiver and exemption rules in detail.
4. Hazardous Nonprescription Products
Competency 3.8 groups hazardous drugs with nonprescription products. In Tennessee this points to USP <800>, which reaches every entity that handles hazardous drugs — including a community pharmacy that merely counts, packages, or stores a NIOSH-listed antineoplastic or a hazardous non-antineoplastic such as a hormone product. Under USP <800>:
- Any hazardous drug on the NIOSH list requires an assessment of risk or full containment.
- Antineoplastic hazardous drugs requiring manipulation, and any hazardous drug active pharmaceutical ingredient, must be handled under full containment controls.
- Even for final dosage forms handled without manipulation, the entity must define and document its assessment of risk and alternative containment strategies.
Section 10.2 covers the engineering controls and personal protective equipment in detail; the point for competency 3.8 is that a nonprescription or unit-of-use product does not escape USP <800> simply because it is never compounded.
5. Practical Exam Scenarios
Scenario 1: The Antitussive Request
Case: A 19-year-old patient the pharmacist does not recognize asks for a 4-ounce bottle of an exempt Schedule V codeine antitussive, and returns the next afternoon asking for a second 4-ounce bottle. Legal Analysis: The first sale is lawful if the pharmacist requires suitable identification, dispenses for a medical purpose, personally makes the dispensing decision, and records the transaction in the bound record book. The second sale is not lawful: under 21 CFR § 1306.32, no more than 120 mL or 24 dosage units of a controlled substance other than an opium preparation may go to the same purchaser in a 48-hour period, and the first 4-ounce (approximately 120 mL) bottle exhausts that allowance.
Scenario 2: Gabapentin at the Register
Case: A technician asks whether gabapentin can be sold from behind the counter without a prescription, reasoning that Tennessee made it Schedule V and Schedule V products can be sold by a pharmacist without a prescription. Legal Analysis: No. The Rule 1140-03-.12(2) pathway applies only to a controlled substance that is not a prescription drug under the FDCA. Gabapentin is an approved prescription drug; Tennessee's scheduling under T.C.A. § 39-17-414 adds controlled substance handling, recordkeeping, and CSMD reporting obligations on top of its prescription status — it does not convert it into an exempt narcotic.
Scenario 3: Unit-Dose Repackaging Without Manufacturer Data
Case: A hospital pharmacy repackages metoprolol into unit-dose blisters. The label shows the drug name, strength, expiration date, and an internal batch code, but no manufacturer name or lot number. Legal Analysis: This is compliant if the pharmacy maintains a readily retrievable record identifying, by that batch number, the manufacturer and lot number. Rule 1140-03-.08(3) expressly authorizes a pharmacy-assigned batch number in lieu of the manufacturer's name and lot number on that condition. Without the cross-reference record, the label violates Rule 1140-03-.08(2)(b).
Under Tenn. Comp. R. & Regs. 1140-03-.12(2) and 21 CFR § 1306.32, a pharmacist may dispense an exempt Schedule V antidiarrheal without a prescription. Which condition is imposed by the federal rule?
A hospital pharmacy repackages a tablet into unit-dose blisters for inpatient use and labels each blister with the drug name, strength, expiration date, and an internal batch number, omitting the manufacturer name and lot number. Under Tenn. Comp. R. & Regs. 1140-03-.08, is this permissible?
Which statement about gabapentin in Tennessee is correct?
A community pharmacy stocks a NIOSH-listed hazardous drug in a manufacturer-sealed final dosage form and never crushes, splits, or otherwise manipulates it. What does USP <800> require?